Protein shake may soothe stomach woes from Weight-Loss drugs
NCT ID NCT07096739
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether drinking a high protein nutrition shake can reduce stomach issues like nausea and vomiting that often come with semaglutide injections (Ozempic or Wegovy). Twenty adults who were already taking semaglutide for weight loss tracked their symptoms for a few days without the shake, then for a week while drinking it daily. The goal was to see if the shake made their stomach problems better.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
20 people
The number who actually took part.
- Started
-
Aug 2025
- Finished
-
Sep 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Generally healthy individuals aged 18-75 years, inclusive * BMI \>27.0kg/m² * Taking semaglutide injections (Ozempic or Wegovy) as prescribed (eg. weekly), for at least 4 weeks prior to screening * Ability to understand the study procedures and willing to provide informed consent to participate in the study * Subjects must be eligible to receive income in Canada and be covered by a health insurance plan such as OHIP * Subjects must have an active e-mail address, daily access to an electronic device (e.g. computer, laptop, tablet, smart phone) and internet, and understand how to complete the daily electronic diary daily Exclusion Criteria: 1. Failure to meet any one of the inclusion criteria 2. Use of a compounded GLP-1 agonist 3. Reported history of metabolic (including type 1 and type 2 diabetes mellitus), hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, psychiatric disorders, or any other medical conditions that, in the judgment of the Principal Investigator, increase the risk to the subject or others or may affect results 4. Hospital admission for major trauma, or major medical or surgical event, as judged by the Principal Investigator, within 6 months of screening 5. Use of medications such as, but not limited to, hypoglycemic agents, systemic steroids, antipsychotics, or any others that increase the risk to the subject or others or may affect results, as judged by the Principal Investigator 6. Known intolerance, sensitivity, or allergy to any ingredients in the study test products 7. Self-reported pregnancy or breastfeeding or less than 6 weeks postpartum 8. Long term treatment with another investigational drug or other intervention within the last 30 days 9. Any condition or diagnosis, that could in the opinion of the Principal Investigator or delegate interfere with the participant's ability to comply with study instructions, might confound the interpretation of the study results, or put the participant at risk
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLP-1 concentration are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Inquis Clinical Research
Toronto, Canada